Dr. Michael Mörz, who works at Hospital Dresden-Friedrichstadt in Germany, did a case report on a 76-year-old man with Parkinson’s disease (PD) who died three weeks after getting his third COVID-19 shot.
The case report was published in the top journal “Vaccines” on Monday.
According to the report, the patient received the Oxford-AstraZeneca COVID-19 vector vaccine in May 2021, followed by the Pfizer-BioNTech vaccine in July and December of that same year.
When the deceased’s family members noticed certain discrepancies in the clinical symptoms that occurred just before the death, they requested for an autopsy to be performed.
From the case report:
The clinical history of the current case showed some remarkable events in correlation to his COVID-19 vaccinations.
Already on the day of his first vaccination in May 2021 (ChAdOx1 nCov-19 vector vaccine), he experienced cardiovascular symptoms, which needed medical care and from which he recovered only slowly. After the second vaccination in July 2021 (BNT162b2 mRNA vaccine), the family recognized remarkable behavioral and psychological changes and a sudden onset of marked progression of his PD symptoms, which led to severe motor impairment and recurrent need for wheelchair support.
He never fully recovered from this but still was again vaccinated in December 2021. Two weeks after this third vaccination (second vaccination with BNT162b2), he suddenly collapsed while taking his dinner. Remarkably, he did not show any coughing or other signs of food aspiration but just fell from his chair.
This raises the question of whether this sudden collapse was really due to aspiration pneumonia. After intense resuscitation, he recovered from this more or less, but one week later, he again suddenly collapsed silently while taking his meal. After successful but prolonged resuscitation attempts, he was transferred to the hospital and directly set into an artificial coma but died shortly thereafter. The clinical diagnosis was death due to aspiration pneumonia. Due to his ambiguous symptoms after the COVID-vaccinations the family asked for an autopsy.
Although there was no history of COVID-19 for this patient, immunohistochemistry for SARS-CoV-2 antigens (spike and nucleocapsid proteins) was performed.
Spike protein could be indeed demonstrated in the areas of acute inflammation in the brain (particularly within the capillary endothelium) and the small blood vessels of the heart. Remarkably, however, the nucleocapsid was uniformly absent. During an infection with the virus, both proteins should be expressed and detected together.
On the other hand, the gene-based COVID-19 vaccines encode only the spike protein and therefore, the presence of spike protein only (but no nucleocapsid protein) in the heart and brain of the current case can be attributed to vaccination rather than to infection. This agrees with the patient’s history, which includes three vaccine injections, the third one just 3 weeks before his death, but no positive laboratory or clinical diagnosis of the infection.
Since the nucleocapsid protein of SARS-CoV-2 was consistently absent, it must be assumed that the presence of spike protein in affected tissues was not due to an infection with SARS-CoV-2 but rather to the transfection of the tissues by the gene-based COVID-19-vaccines,” Dr. Mörz stated.
“This is strongly suggestive that the spike protein may have played at least a contributing role to the development of the lesions and the course of the disease in this patient,” he added.
In his conclusion, Dr. Mörz stated, “Numerous cases of encephalitis and encephalomyelitis have been reported in connection with the gene-based COVID-19 vaccines, with many being considered causally related to vaccination. However, this is the first report to demonstrate the presence of the spike protein within the encephalitic lesions and to attribute it to vaccination rather than infection. These findings corroborate a causative role of the gene-based COVID-19 vaccines, and this diagnostic approach is relevant to potentially vaccine-induced damage to other organs as well.”
Full Report Below
Background Post: Why I Boosted with Novavax
Ok, my hand was forced because we booked a transatlantic cruise for November, after which the company informed us proof of a Covid booster shot would be required to board the ship in Civitavecchia (Rome). My blood test last December showed plenty of antibodies and I’ve tested negative for Sars CV2 many times. For reasons described later on, I do not want more gene therapy experimentation in my body. Fortunately, Novavax is now approved and available, and I got boosted with a real vaccine shot yesterday in Montreal where I live.
How is Novavax different than the other COVID-19 vaccines in the U.S.?
Though COVID vaccines may utilize different delivery mechanisms, the end result is the same: cells in the body recognize that a spike protein (the spikes you see sticking out of the coronavirus in pictures) doesn’t belong, and the immune system reacts by activating immune cells and producing antibodies to attack the real virus if you get exposed.
But, unlike the other vaccines, Novavax directly injects a version of the spike protein, along with another ingredient that also stimulates the immune system, into the body, leading to the production of antibodies and T-cells. (It injects a version of the spike protein that has been formulated in a laboratory as a nanoparticulate that does not have genetic material inside and cannot cause disease.)
“I often tell people, imagine an eggshell without an egg in it. That’s what it is,” Dr. Wilson says.
The Novavax vaccine is a traditional one compared to the other vaccines. Its technology has been used before in vaccines to prevent such conditions as shingles, human papillomavirus, and DTaP (diphtheria, tetanus, and pertussis), among others.
Has the Novavax vaccine been authorized outside of the U.S.?
Yes. The Novavax coronavirus vaccine (brand names: Nuvaxovid and Covovax) is already being used to prevent the coronavirus in 40 other countries, including Canada.
Novavax is based in Maryland, and the vaccine was developed in the U.S. in 2020 with support from the federal government program Operation Warp Speed, but it’s progress was slowed by manufacturing difficulties. Finally, in November 2021, countries around the world, starting with Indonesia and the Philippines, later followed by the United Kingdom, began granting authorizations for the vaccine.
Novavax applied to the FDA for authorization in January of this year.
- The European Commission has approved the expanded conditional approval of Novavax Inc’s (NASDAQ: NVAX) Nuvaxovid COVID-19 vaccine as a homologous and heterologous booster for adults aged 18 and older.
- The approval follows the recommendation made by the European Medicines Agency’s Committee for Medicinal Products for Human Use earlier this month.
- The expanded approval was based on data from Novavax’s Phase 2 trial conducted in Australia, a separate Phase 2 trial conducted in South Africa, and the UK-sponsored COV-BOOST trial.
- The third dose produced increased immune responses comparable to or exceeding levels associated with protection in Phase 3 trials. In the COV-BOOST trial, Nuvaxovid induced a robust antibody response when used as a heterologous third booster dose.
- In the Novavax-sponsored trials, local and systemic reactions were generally short-lived following the booster.
- Nuvaxovid has also been authorized in Japan, Australia, and New Zealand as a booster in adults aged 18 and older and is actively under review in other markets.
A Distinction Which is a Real Difference
My discomfort with mRNA shots is multiple: The trial data from Pfizer and Moderna is still being withheld; the trial period was too short to reveal any long-term side effects; the companies were given total immunity from liability for damage to people injected with their products. And, they unscrupulously trashed effective generic viral treatments like Hydroxychloroquine and Ivermectin to protect their vaccine payday. A more detailed analysis is below.
From Joseph Mercola writing at Bright Health News COVID-19 ‘Vaccines’ Are Gene Therapy Excerpts in italics with my bolds.
Not a vaccine in the medical definition, the COVID-19 ‘vaccine’ is really an experimental gene therapy that does not render immunity or prevent infection or transmission of the disease.
mRNA “vaccines” created by Moderna and Pfizer are gene therapies. They fulfill all the definitions of gene therapy and none of the definitions for a vaccine. This matters because you cannot mandate a gene therapy against COVID-19 any more than you can force entire populations to undergo gene therapy for a cancer they do not have and may never be at risk for
mRNA contain genetic instructions for making various proteins. mRNA “vaccines” deliver a synthetic version of mRNA into your cells that carry the instruction to produce the SARS-CoV-2 spike protein, the antigen, that then activates your immune system to produce antibodies
The only one benefiting from an mRNA “vaccine” is the vaccinated individual, since all they are designed to do is lessen clinical symptoms associated with the S-1 spike protein. Since you’re the only one who will reap a benefit, it makes no sense to demand you accept the risks of the therapy “for the greater good” of your community
Since mRNA “vaccines” do not meet the medical and/or legal definition of a vaccine — at least not until the CDC redefined “vaccine” — marketing them as such is a deceptive practice that violates the law that governs advertising of medical practices
SARS-CoV-2 has not even been proven to be the cause of COVID-19. So, a gene therapy that instructs your body to produce a SARS-CoV-2 antigen — the viral spike protein — cannot be said to be preventive against COVID-19, as the two have not been shown to be causally linked
Illegal to Promote mRNA Products without Evidence of Safety and Effectiveness
The lack of completed human trials also puts these mRNA products at odds with 15 U.S. Code Section 41. Per this law, it is unlawful to advertise “that a product or service can prevent, treat, or cure human disease unless you possess competent and reliable scientific evidence, including, when appropriate, well-controlled human clinical studies, substantiating that the claims are true at the time they are made.”
Here’s the problem: The primary end point in the COVID-19 “vaccine” trials is not an actual vaccine trial end point because, again, vaccine trial end points have to do with immunity and transmission reduction. Neither of those was measured.
What’s more, key secondary end points in Moderna’s trial include prevention of severe COVID-19 disease (defined as need for hospitalization) and prevention of infection by SARS-CoV-2, regardless of symptoms.[15 However, Moderna did not actually measure rate of infection, stating that it was too “impractical” to do so.
That means there’s no evidence of this gene therapy having an impact on infection, for better or worse. And, if you have no evidence, you cannot fulfill the U.S. Code requirement that states you must have “competent and reliable scientific evidence … substantiating that the claims are true.”
Making matters worse, both Pfizer and Moderna eliminated their control groups by offering the real vaccine to any and all placebo recipients who want it. The studies are supposed to go on for a full two years, but by eliminating the control group, determining effectiveness and risks is going to be near impossible.
Gene Therapy is a Last Resort, not the First Response
Here, it’s worth noting that there are many different treatments that have been shown to be very effective against COVID-19, so it certainly does not qualify as a disease that has no cure. For example, research shows the antiparasitic ivermectin impairs the SARS-CoV-2 spike protein’s ability to attach to the ACE2 receptor on human cell membranes.
It also can help prevent blood clots by binding to SARS-CoV-2 spike protein. This prevents the spike protein from binding to CD147 on red blood cells and triggering clumping.
It makes sense, then, that gene therapy should be restricted to incurable diseases, as this is the only time that taking drastic risks might be warranted. That said, here’s how the U.S. Food and Drug Administration defines gene therapy:
“Human gene therapy seeks to modify or manipulate the expression of a gene or to alter the biological properties of living cells for therapeutic use. Gene therapy is a technique that modifies a person’s genes to treat or cure disease. Gene therapies can work by several mechanisms:
- Replacing a disease-causing gene with a healthy copy of the gene
- Inactivating a disease-causing gene that is not functioning properly
- Introducing a new or modified gene into the body to help treat a disease”
Experimental Gene Therapy Is a Bad Idea
I’ve written many articles detailing the potential and expected side effects of these gene therapy “vaccines.”
The take-home message here is that these injections are not vaccines. They do not prevent infection, they do not render you immune and they do not prevent transmission of the disease. Instead, they alter your genetic coding, turning you into a viral protein factory that has no off-switch. What’s happening here is a medical fraud of unprecedented magnitude, and it really needs to be stopped before it’s too late for a majority of people.
If you already got the vaccine and now regret it, you may be able to address your symptoms using the same strategies you’d use to treat actual SARS-CoV-2 infection. And, last but not least, if you got the vaccine and are having side effects, please help raise public awareness by reporting it. The Children’s Health Defense is calling on all who have suffered a side effect from a COVID-19 vaccine to do these three things:
- If you live in the U.S., file a report on VAERS
- Report the injury on VaxxTracker.com, which is a nongovernmental adverse event tracker (you can file anonymously if you like)
- Report the injury on the CHD website
via Science Matters
October 2, 2022 at 10:56AM